<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40937412</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Correlation of serum irisin levels with diabetic nephropathy: an exhaustive systematic appraisal and meta-analytical investigation.</ArticleTitle><Pagination><StartPage>1599423</StartPage><MedlinePgn>1599423</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1599423</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2025.1599423</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Diabetic nephropathy (DN) is a major complication of diabetes, contributing significantly to end - stage renal disease. Irisin, an exercise - induced myokine, has been linked to metabolic disorders, but its relationship with DN remains unclear. This study aims to comprehensively and accurately explore the association between serum irisin levels and DN through a systematic review and meta - analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The research was conducted following the Meta - analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Multiple electronic databases, including Cochrane Library, Embase, Web of Science, PubMed, China National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBM), and Wanfang Database, were systematically searched using relevant keywords related to irisin and DN. Studies were included if they were randomized controlled trials (RCTs) or observational studies that stratified Type 2 diabetes mellitus (T2DM) patients based on the presence or absence of DN, measured serum irisin levels in both groups, and provided data in a suitable format. Two independent reviewers performed literature screening, data extraction, and quality assessment. The Jadad scale was used for RCTs, and the Newcastle - Ottawa Scale (NOS) was applied for cohort and case - control studies. Statistical analysis was carried out using RevMan 5.3 software, with heterogeneity evaluated by Q and I&#xb2; tests, and appropriate models (fixed - effects or random - effects) selected accordingly. INPLASY registration number:202530056.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of seven studies, comprising 453 DN patients and 346 non-DN controls, were included in the final meta-analysis. The pooled results demonstrated that serum irisin levels were significantly lower in patients with diabetic nephropathy, particularly those with more advanced stages of albuminuria. Specifically, irisin levels were significantly reduced in patients with microalbuminuria (MD = 30.84, 95% CI: 7.81 to 53.87, I&#xb2; = 96%) and macroalbuminuria (MD = 30.84, 95% CI: 7.81 to 53.87, I&#xb2; = 98%) compared to those with normoalbuminuria. Furthermore, a direct comparison between microalbuminuria and macroalbuminuria also revealed significantly lower irisin levels in the latter group (MD = 12.53, 95% CI: 3.46 to 21.59, I&#xb2; = 89%). In terms of renal function, patients with eGFR &lt; 60 mL/min/1.73 m&#xb2; exhibited lower irisin concentrations than those with preserved renal function (MD = 3.43, 95% CI: -2.90 to 9.75, I&#xb2; = 90%), though this difference was not statistically significant. Given the substantial heterogeneity among the included studies, random-effects models were applied for all analyses. Funnel plot assessment showed general symmetry in most comparisons, indicating a low to moderate risk of publication bias, although asymmetry was observed in the microalbuminuria vs. macroalbuminuria subgroup, suggesting potential small-study effects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This meta-analysis provides evidence for an association between serum irisin levels and DN. Lower serum irisin levels were related to more severe albuminuria and decreased eGFR in T2DM patients. However, considering the limitations of this study, such as potential missing data and methodological differences, further large - scale, multi-center, and high-quality RCTs are needed to validate these findings and elucidate the underlying mechanisms.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">INPLASY.COM, identifier 202530056.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Deng, Shen, Wu, Wen and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nursing, Yueyang Vocational Technical College, Yueyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yinhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nursing, Yueyang Vocational Technical College, Yueyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nursing, Yueyang Vocational Technical College, Yueyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nursing, Yueyang Vocational Technical College, Yueyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Health Management, Xianning Vocational Technical College, Xianning,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577593">FNDC5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005353" MajorTopicYN="Y">Fibronectins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diabetic nephropathy</Keyword><Keyword MajorTopicYN="N">irisin</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40937412</ArticleId><ArticleId IdType="pmc">PMC12420281</ArticleId><ArticleId IdType="doi">10.3389/fendo.2025.1599423</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Russo G, Piscitelli P, Giandalia A, Viazzi F, Pontremoli R, Fioretto P, et al. Atherogenic dyslipidemia and diabetic nephropathy. J Nephrol. (2020) 33:1001&#x2013;8. doi:&#xa0; 10.1007/s40620-020-00739-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-020-00739-8</ArticleId><ArticleId IdType="pubmed">32328901</ArticleId></ArticleIdList></Reference><Reference><Citation>Donate-Correa J, Luis-Rodriguez D, Martin-Nunez E, Tagua VG, Hernandez-Carballo C, Ferri C, et al. Inflammatory targets in diabetic nephropathy. J Clin Med. (2020) 9(2):458. doi:&#xa0; 10.3390/jcm9020458, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020458</ArticleId><ArticleId IdType="pmc">PMC7074396</ArticleId><ArticleId IdType="pubmed">32046074</ArticleId></ArticleIdList></Reference><Reference><Citation>Al MA, Ara MA, Wu Y, Zaeem M, Abdul AM, Aktar SS, et al. Pyroptosis in diabetic nephropathy. Clin Chim Acta. (2021) 523:131&#x2013;43. doi:&#xa0; 10.1016/j.cca.2021.09.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.09.003</ArticleId><ArticleId IdType="pubmed">34529985</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. (2020) 2067:3&#x2013;7. doi:&#xa0; 10.1007/978-1-4939-9841-8_1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9841-8_1</ArticleId><ArticleId IdType="pubmed">31701441</ArticleId></ArticleIdList></Reference><Reference><Citation>elle MC, Provenzano M, Busutti M, Porcu CV, Zaffina I, Stanga L, et al. Up-date on diabetic nephropathy. Life (Basel). (2022) 12(8):1202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9409996</ArticleId><ArticleId IdType="pubmed">36013381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Liu D, Feng Q, Liu Z. Diabetic nephropathy: perspective on extracellular vesicles. Front Immunol. (2020) 11:943. doi:&#xa0; 10.3389/fimmu.2020.00943, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00943</ArticleId><ArticleId IdType="pmc">PMC7283536</ArticleId><ArticleId IdType="pubmed">32582146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaf H, Thomas G, Taliercio JJ, Nakhoul G, Vachharajani TJ, Mehdi A. Therapeutic advances in diabetic nephropathy. J Clin Med. (2022) 11:378. doi:&#xa0; 10.3390/jcm11020378, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020378</ArticleId><ArticleId IdType="pmc">PMC8781778</ArticleId><ArticleId IdType="pubmed">35054076</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Jian Z, Wang H, Xu L, Zhang T, Song J. Irisin Promotes Osteogenesis by Modulating Oxidative Stress and Mitophagy through SIRT3 Signaling under Diabetic Conditions. Oxid Med Cell LONGEV. (2022) 2022:3319056. doi:&#xa0; 10.1155/2022/3319056, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/3319056</ArticleId><ArticleId IdType="pmc">PMC9576424</ArticleId><ArticleId IdType="pubmed">36262283</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clin Sci (Lond). (2015) 129:839&#x2013;50. doi:&#xa0; 10.1042/CS20150009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20150009</ArticleId><ArticleId IdType="pubmed">26201094</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yan S, Luo L, Yang L. Irisin regulates the expression of BDNF and glycometabolism in diabetic rats. Mol Med Rep. (2019) 19:1074&#x2013;82. doi:&#xa0; 10.3892/mmr.2018.9743, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.9743</ArticleId><ArticleId IdType="pmc">PMC6323232</ArticleId><ArticleId IdType="pubmed">30569121</ArticleId></ArticleIdList></Reference><Reference><Citation>Foad AM, Hafez A, Youssef W, Ahmed AE, Altaher AM. Irisin expression and FNDC5 (rs3480) gene polymorphism in type 2 diabetic patients with and without CAD. Arch Physiol Biochem. 2023:1&#x2013;6. doi:&#xa0; 10.1080/13813455.2023.2173785, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13813455.2023.2173785</ArticleId><ArticleId IdType="pubmed">36732920</ArticleId></ArticleIdList></Reference><Reference><Citation>
Colaianni G, Cuscito C, Mongelli T, Oranger A, Mori G, Brunetti G, et al. Irisin enhances osteoblast differentiation <i>in vitro</i>
. Int J Endocrinol. (2014) 2014:902186. doi:&#xa0; 10.1155/2014/902186, PMID: 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/902186</ArticleId><ArticleId IdType="pmc">PMC3960733</ArticleId><ArticleId IdType="pubmed">24723951</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JJ, Liu S, Wong MD, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complicat. (2014) 28:208&#x2013;13. doi:&#xa0; 10.1016/j.jdiacomp.2013.09.011, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2013.09.011</ArticleId><ArticleId IdType="pubmed">24332937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HH, Zhang XW, Chen WK, et al. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. J Diabetes Complicat. (2015) 29:384&#x2013;9. doi:&#xa0; 10.1016/j.jdiacomp.2015.01.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2015.01.001</ArticleId><ArticleId IdType="pubmed">25623634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Wang R, Li J, et al. Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy. Ann Clin Biochem. (2016) 53:67&#x2013;74. doi:&#xa0; 10.1177/0004563215582072, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0004563215582072</ArticleId><ArticleId IdType="pubmed">25814621</ArticleId></ArticleIdList></Reference><Reference><Citation>Khidr EG, Ali SS, Elshafey MM, et al. Association of irisin and FNDC5 rs16835198 G &gt; T gene polymorphism with type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene. (2017) 626:26&#x2013;31. doi:&#xa0; 10.1016/j.gene.2017.05.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2017.05.010</ArticleId><ArticleId IdType="pubmed">28479383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha JJ, Min HS, Kim K, et al. Long-term study of the association of adipokines and glucose variability with diabetic complications. Korean J Intern Med. (2018) 33:367&#x2013;82. doi:&#xa0; 10.3904/kjim.2016.114, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2016.114</ArticleId><ArticleId IdType="pmc">PMC5840591</ArticleId><ArticleId IdType="pubmed">27809453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageswari R, Sridhar MG, Nandeesha H, et al. Irisin and visfatin predicts severity of diabetic nephropathy. Indian J Clin Biochem. (2019) 34:342&#x2013;6. doi:&#xa0; 10.1007/s12291-018-0749-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-018-0749-7</ArticleId><ArticleId IdType="pmc">PMC6660529</ArticleId><ArticleId IdType="pubmed">31391726</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelbaya S, Abu Shady MM, Nasr MS, et al. Study of irisin hormone level in type 2 diabetic patients and patients with diabetic nephropathy. Curr Diabetes Rev. (2018) 14:481&#x2013;6. doi:&#xa0; 10.2174/1573399813666170829163442, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573399813666170829163442</ArticleId><ArticleId IdType="pubmed">28875825</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezina TA, Berezin OO, Hoppe UC, Lichtenauer M, Berezin AE. Trajectory of irisin as a predictor of kidney-related outcomes in patients with asymptomatic heart failure. Biomedicines. (2024) 12:1827. doi:&#xa0; 10.3390/biomedicines12081827, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12081827</ArticleId><ArticleId IdType="pmc">PMC11352030</ArticleId><ArticleId IdType="pubmed">39200291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Lee S, Jang H, Jung S, Jung MH, Yun JW, et al. Transcriptional Intermediary Factor 1&#x3b3;-Induced Irisin in Skeletal Muscle Attenuates Renal Fibrosis in Diabetic Nephropathy. J Cachexia Sarcopenia Muscle. (2025) 16:e13810. doi:&#xa0; 10.1002/jcsm.13810, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.13810</ArticleId><ArticleId IdType="pmc">PMC12000539</ArticleId><ArticleId IdType="pubmed">40235186</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z, Fang Y, Xing T, Wang F. Diabetic nephropathy: from pathophysiology to treatment. J Diabetes Res. (2017) 2017:2379432. doi:&#xa0; 10.1155/2017/2379432, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2379432</ArticleId><ArticleId IdType="pmc">PMC5672629</ArticleId><ArticleId IdType="pubmed">29201920</ArticleId></ArticleIdList></Reference><Reference><Citation>John S. Complication in diabetic nephropathy. Diabetes Metab Syndr. (2016) 10:247&#x2013;9. doi:&#xa0; 10.1016/j.dsx.2016.06.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2016.06.005</ArticleId><ArticleId IdType="pubmed">27389078</ArticleId></ArticleIdList></Reference><Reference><Citation>Elesawy BH, Askary AE, Mehanna OM, Elmorsy EA, Khalifa MM, Ali SE, et al. High serum levels of irisin, visfatin and adiponectin as potential independent risk factors for diabetic nephropathy progression in patients with type 2 diabetes mellitus. In Vivo. (2025) 39:1615&#x2013;24. doi:&#xa0; 10.21873/invivo.13962, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.13962</ArticleId><ArticleId IdType="pmc">PMC12041983</ArticleId><ArticleId IdType="pubmed">40294981</ArticleId></ArticleIdList></Reference><Reference><Citation>Juin SK, Ouseph R, Gondim DD, Jala VR, Sen U. Diabetic nephropathy and gaseous modulators. Antioxidants (Basel). (2023) 12:1088. doi:&#xa0; 10.3390/antiox12051088, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12051088</ArticleId><ArticleId IdType="pmc">PMC10215699</ArticleId><ArticleId IdType="pubmed">37237955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, Guo Y, Xia Y, Li C, Xu X, Qi T, et al. FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin alphaV/beta5-AKT signaling and reduction of oxidative/nitrosative stress. J Mol Cell Cardiol. (2021) 160:27&#x2013;41. doi:&#xa0; 10.1016/j.yjmcc.2021.06.013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2021.06.013</ArticleId><ArticleId IdType="pubmed">34224725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada T. Serum irisin and diabetic nephropathy in patients with diabetes mellitus. Horm Metab Res. (2021) 53:825. doi:&#xa0; 10.1055/a-1676-4118, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1676-4118</ArticleId><ArticleId IdType="pubmed">34891213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Liu H. Association between serum irisin and diabetic nephropathy in patients with type 2 diabetes mellitus: A meta-analysis. Horm Metab Res. (2021) 53:293&#x2013;300. doi:&#xa0; 10.1055/a-1475-4444, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1475-4444</ArticleId><ArticleId IdType="pubmed">33962476</ArticleId></ArticleIdList></Reference><Reference><Citation>Formigari GP, Datilo MN, Vareda B, Bonfante I, Cavaglieri CR, Lopes DFJ, et al. Renal protection induced by physical exercise may be mediated by the irisin/AMPK axis in diabetic nephropathy. Sci Rep. (2022) 12:9062. doi:&#xa0; 10.1038/s41598-022-13054-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13054-y</ArticleId><ArticleId IdType="pmc">PMC9156698</ArticleId><ArticleId IdType="pubmed">35641586</ArticleId></ArticleIdList></Reference><Reference><Citation>Formigari GP, Datilo MN, Vareda B, Bonfante I, Cavaglieri CR, Lopes DFJ, et al. Renal protection induced by physical exercise may be mediated by the irisin/AMPK axis in diabetic nephropathy. Sci Rep. (2022) 12:9062. doi:&#xa0; 10.1038/s41598-022-13054-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13054-y</ArticleId><ArticleId IdType="pmc">PMC9156698</ArticleId><ArticleId IdType="pubmed">35641586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Song F, Xu K, Liu Z, Han S, Li F, et al. Irisin attenuates neuroinflammation and prevents the memory and cognitive deterioration in streptozotocin-induced diabetic mice. Mediators Inflammation. (2019) 2019:1567179. doi:&#xa0; 10.1155/2019/1567179, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1567179</ArticleId><ArticleId IdType="pmc">PMC6590589</ArticleId><ArticleId IdType="pubmed">31281225</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsanathan R, Jain SK. Hydrogen sulfide regulates irisin and glucose metabolism in myotubes and muscle of HFD-fed diabetic mice. Antioxidants (Basel). (2022) 11(7):1369. doi:&#xa0; 10.3390/antiox11071369, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11071369</ArticleId><ArticleId IdType="pmc">PMC9311985</ArticleId><ArticleId IdType="pubmed">35883859</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorasani ZM, Bagheri RK, Yaghoubi MA, Chobkar S, Aghaee MA, Abbaszadegan MR, et al. The association between serum irisin levels and cardiovascular disease in diabetic patients. Diabetes Metab Syndr. (2019) 13:786&#x2013;90. doi:&#xa0; 10.1016/j.dsx.2018.11.050, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2018.11.050</ArticleId><ArticleId IdType="pubmed">30641808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Q, Song R, Zhao X, Yang C, Feng Y. Lower circulating irisin levels in type 2 diabetes mellitus patients with chronic complications: A meta-analysis. Heliyon. (2023) 9:e21859. doi:&#xa0; 10.1016/j.heliyon.2023.e21859, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e21859</ArticleId><ArticleId IdType="pmc">PMC10658327</ArticleId><ArticleId IdType="pubmed">38027674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ersahin SS, Yurci A. Cord blood and maternal serum preptin and irisin concentrations are regulated independently in GDM. Eur Rev Med Pharmacol Sci. (2021) 25:1954&#x2013;8. doi:&#xa0; 10.26355/eurrev_202102_25095, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202102_25095</ArticleId><ArticleId IdType="pubmed">33660805</ArticleId></ArticleIdList></Reference><Reference><Citation>Azushima K, Gurley SB, Coffman TM. Modelling diabetic nephropathy in mice. Nat Rev Nephrol. (2018) 14:48&#x2013;56. doi:&#xa0; 10.1038/nrneph.2017.142, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.142</ArticleId><ArticleId IdType="pubmed">29062142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>